CNTB News and Press, Connect Biopharma Holdings Limited From 10/10/22

Summary Lead product candidate CBP-201 had a successful pivotal trial. After an initial surge, traders selling the news brought prices 15% below the previous close. CBP-201 is now on a near-certain path to approval in the world's 2nd largest market. (Editor's Note:...

Summary Beijing AIM Vaccine conducted a very small IPO on the Hong Kong exchange, raising just US$20 million, which netted the company only US$10 million. Interest in the offering was low, with less than 1% of the company shares sold in the offering. Shanghai SciClone Pharma has b...

Connect Biopharma ( NASDAQ: CNTB ) stock fell ~3% on Oct. 4 despite the company saying that CBP-201 helped patients with atopic dermatitis (AD) achieve clear or almost clear skin, meeting the main goal of phase 2b trial in China. In the study, patients...

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the "About the Trial" section, the fourth sentence should read "Stage 2 36-week maintenanc...

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathway Data support advancing the regulatory discussions wit...

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company develo...

Summary The stock is down 80% year-to-date due to disappointing study results from the company’s two lead product candidates, CBP-201 and CBP-307. CBP-307 development has been put on ice. But CBP-201 is back, and if more successful this time, it could be on a fast track...

Connect Biopharma Holdings Limited (CNTB) Q2 2022 Results Conference Call September 13, 2022 04:30 PM ET Company Participants Ina McGuinness - IR Dr. Zheng Wei - Co-Founder and CEO Dr. Chin Lee - Chief Medical Officer Steven Chan - CFO Conference Call P...

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflamm...

– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU, China, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limit...